Luseogliflozin Suppresses Late-Night Basal Glycemic Variability in Type 2 Diabetes: A Retrospective Observational Study.

Cureus · 2025 · PMC12670329 · PMID 41341349

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

did not reach statistical significancep = 0.058so close (0.05 < p ≤ 0.1)

After luseogliflozin administration, fasting plasma glucose showed a modest reduction (from 8.6 ± 1.4 to 7.5 ± 1.0 mmol/L), but this difference did not reach statistical significance (p = 0.058).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.